|
ABSTRACTS
Angiotensin-(1-7) Stimulates Hematopoietic Progenitor Cells in Vitro and in Vivo
Effects of angiotensin (Ang)-(1-7), an AngII metabolite, on bone marrow-derived hematopoietic cells were studied.
SATB1 Defines the Developmental Context for Gene Silencing by Xist in Lymphoma and Embryonic Cells
This study identifies the special AT-rich binding protein SATB1 as an essential silencing factor.
Efficient Production of Mesencephalic Dopamine Neurons by Lmx1a Expression in Embryonic Stem Cells
This study shows that forced expression of Lmx1a, a transcription factor functioning as a determinant of mesDA neurons during embryogenesis, effectively can promote the generation of mesDA neurons from mouse and human ESCs.
SATB1 Defines the Developmental Context for Gene Silencing by Xist in Lymphoma and Embryonic Cells
The researchers show here that Xist, a silencer of one of the two female X chromosomes, can initiate silencing in a lymphoma model.
Generation of Induced Pluripotent Stem Cell Lines from Tibetan Miniature Pig
Reported here is report the successful generation of pluripotent stem cells from fibroblasts isolated from Tibetan miniature pig using a modified iPS protocol.
Sall4 Is Essential for Stabilization, But Not for Pluripotency, of Embryonic Stem Cells by Repressing Aberrant Trophectoderm Gene Expression
This study reports that, in the absence of feeder cells, Sall4-null ES cells express the trophectoderm marker Cdx2, but are maintained for a long period in an undifferentiated state with minimally affected Oct3/4 expression.
p66ShcA Adaptor Molecule Accelerates ES Cell Neural Induction
This study reports that p66ShcA is up-regulated during in vitro neural induction in embryonic stem cells.
Specific Knockdown of OCT4 in Human Embryonic Stem Cells by Inducible Short Hairpin RNA Interference
This report demonstrates a tetracycline-inducible short hairpin RNA interference for human embryonic stem cells and demonstrated doxycycline dose-dependent knockdown of the transcription factor OCT4 and the cell surface antigen ??2-microglobulin.
|
|
INDUSTRY
STEMCELL Technologies Introduces a New Animal Component-Free, Serum-Free Medium for Culturing Human Mesenchymal Stem Cells
STEMCELL Technologies, Inc. recently announced the release of MesenCult(R)-ACF Medium, the first defined, animal component-free and serum-free medium for culturing human mesenchymal stem cells. MesenCult®-ACF Medium supports long-term growth of MSCs with retention of multi-lineage differentiation potential.
University College London-Pfizer to Develop Pioneering Stem Cell Sight Therapies
UCL has entered into a collaboration with the biopharmaceutical group Pfizer to advance development of stem cell-based therapies for age-related macular degeneration.
University of Utah Cell Therapy Lab Collaborates with Q Therapeutics on Stem Cell Therapy to Fight Lou Gehrig's Disease
With $5 million dollars in funding from the National Institutes of Health, the University of Utah's Cell Therapy Facility and spin-out Q Therapeutics, Inc. have teamed up to bring the cell-based therapy to the point of human clinical trials to treat amyotrophic lateral sclerosis.
Fate Therapeutics and Stemgent Launch Catalyst: A Unique Industry Program for First Access to the Most Advanced Induced Pluripotent Stem Cell Technology
Fate Therapeutics, Inc. and Stemgent, Inc. announced recently the formation of Catalyst, a collaborative one-of-a-kind program to provide pharmaceutical and biotechnology companies with an induced pluripotent stem cell technology platform for drug discovery and development.
Roche Madison Opens Facility in University Research Park
The Madison subsidiary is focused in the areas of RNA interference and gene therapy, which plans to hire more employees during the next six to 12 months, has opened a new facility Thursday in University Research Park.
Credit Crisis Puts Canadian Biotech at Risk
The global credit crisis threatens to put many of Canada's biotech companies out of business and choke off the country's role in a key sector of the future economy, a study says.
Alnylam Announces Allowance in Europe of New Fundamental Patent Broadly Covering RNAi Therapeutics
Alnylam Pharmaceuticals announced recently that the European Patent Office has issued a notification of intent to grant for a patent in the Tuschl I patent series covering the use of double stranded RNAs for RNAi.
|
|
|
This email was sent by: Connexon Creative
400-570 W. 7th Avenue Vancouver, British Columbia V5Z 1B3 Canada |
|
|
